Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL615023 Target Snapshot

U2OS · CELL-LINE · Homo sapiens

4,015Compounds
965Assays
38Approved Drugs
1,417.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats U2OS as ChEMBL target CHEMBL615023. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
U2OS
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL615023
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether U2OS still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelU2OS
UniProt AccessionN/A

U2OS

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as U2OS.

Review nameU2OS
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

38
Approved
13
Phase III
16
Phase II
8
Phase I
Assay Mix

Activity Type Distribution

IC501,260.0
EC50157.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL94657 9.98 IC50 0.104 Clinical
CHEMBL439967 9.42 IC50 0.38 Preclinical
CHEMBL67 9.12 IC50 0.766 Preclinical
CHEMBL113712 8.82 IC50 1.5 Preclinical
CHEMBL3545252 8.76 IC50 1.752 Approved
CHEMBL2137046 8.72 IC50 1.9 Preclinical
CHEMBL1807305 8.7 IC50 2.0 Preclinical
CHEMBL1807303 8.7 IC50 2.0 Preclinical
CHEMBL2180985 8.66 IC50 2.2 Preclinical
CHEMBL81 8.51 IC50 3.1 Approved
Distribution

pChEMBL Value Distribution

201
5.0
160
5.5
139
6.0
74
6.5
57
7.0
36
7.5
11
8.0
7
8.5
2
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

CERITINIB
CHEMBL2403108
Approved 2014
PONATINIB
CHEMBL1171837
Approved 2012
TEMSIROLIMUS
CHEMBL1201182
Approved 2007
ROSIGLITAZONE
CHEMBL121
Approved 1999
RALOXIFENE
CHEMBL81
Approved 1997
GEMCITABINE
CHEMBL888
Approved 1996
DOCETAXEL
CHEMBL3545252
Approved 1995
PACLITAXEL
CHEMBL428647
Approved 1992
IDARUBICIN
CHEMBL1117
Approved 1990
DAUNORUBICIN
CHEMBL178
Approved 1979
DOXORUBICIN
CHEMBL53463
Approved 1974
CYTARABINE
CHEMBL803
Approved 1969
VINBLASTINE
CHEMBL159
Approved 1965
MELPHALAN
CHEMBL852
Approved 1964
DACTINOMYCIN
CHEMBL1554
Approved 1964
METHOTREXATE
CHEMBL34259
Approved 1953
Assay Landscape

Assay Landscape

965
Total Assays
937
Tested Compounds
3
Assay Types
Functional — 884 assays, 937 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 868 937 5.6
organism-based format 16 0
ADME — 62 assays, 37 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 62 37 5.5
Toxicity — 19 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 19 1 7.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine